小方制药：委托博济医药开发中药1.1类新药复方侧柏酊

Core Viewpoint - The company, Xiao Fang Pharmaceutical, has signed a technical entrustment contract with Boji Pharmaceutical to assist in the clinical research and registration of a new traditional Chinese medicine, Compound Cypraea Tincture, which is classified as a Class 1 new drug [1] Group 1 - The collaboration aims to facilitate the completion of clinical trials and the subsequent market launch of the new drug [1] - This transaction does not constitute a major asset restructuring or a related party transaction [1] - The agreement is not expected to have a significant impact on the company's operating results for the current fiscal year [1]